Amgen Inc (AMGN)vsBP PLC ADR (BP)
AMGN
Amgen Inc
$331.70
+0.79%
HEALTHCARE · Cap: $177.71B
BP
BP PLC ADR
$43.34
-1.07%
ENERGY · Cap: $114.92B
Smart Verdict
WallStSmart Research — data-driven comparison
BP PLC ADR generates 419% more annual revenue ($193.00B vs $37.22B). AMGN leads profitability with a 21.0% profit margin vs 1.7%. BP appears more attractively valued with a PEG of 0.05. BP earns a higher WallStSmart Score of 65/100 (B-).
AMGN
Buy62
out of 100
Grade: C+
BP
Strong Buy65
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-2.2%
Fair Value
$321.89
Current Price
$331.70
$9.81 premium
Margin of Safety
+26.9%
Fair Value
$52.77
Current Price
$43.34
$9.43 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 101 in profit
Strong operational efficiency at 33.8%
Large-cap with strong market position
Keeps 21 of every $100 in revenue as profit
Generating 1.5B in free cash flow
Growing faster than its price suggests
Earnings expanding 474.5% YoY
Large-cap with strong market position
Areas to Watch
Expensive relative to growth rate
Trading at 19.5x book value
4.4% earnings growth
Premium valuation, high expectations priced in
Trading at 8.4x book value
ROE of 5.8% — below average capital efficiency
1.7% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AMGN
The strongest argument for AMGN centers on Return on Equity, Operating Margin, Market Cap. Profitability is solid with margins at 21.0% and operating margin at 33.8%.
Bull Case : BP
The strongest argument for BP centers on PEG Ratio, EPS Growth, Market Cap. Revenue growth of 11.6% demonstrates continued momentum. PEG of 0.05 suggests the stock is reasonably priced for its growth.
Bear Case : AMGN
The primary concerns for AMGN are PEG Ratio, Price/Book, EPS Growth.
Bear Case : BP
The primary concerns for BP are P/E Ratio, Price/Book, Return on Equity. Thin 1.7% margins leave little buffer for downturns.
Key Dynamics to Monitor
AMGN profiles as a mature stock while BP is a value play — different risk/reward profiles.
AMGN carries more volatility with a beta of 0.43 — expect wider price swings.
BP is growing revenue faster at 11.6% — sustainability is the question.
AMGN generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
BP scores higher overall (65/100 vs 62/100) and 11.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amgen Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
Visit Website →BP PLC ADR
ENERGY · OIL & GAS INTEGRATED · USA
BP plc participates in the energy business globally. The company is headquartered in London, the United Kingdom.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?